---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-045526"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2026-02-11T23:59:59+00:00"
generated_at: "2026-05-16T03:23:13.689851+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Neumora Therapeutics releases corporate presentation at Guggenheim summit; no material details disclosed

## Summary
- Presentation dated February 2026 made available for Guggenheim Emerging Outlook: Biotech Summit.
- No financial results, pipeline updates, or guidance changes were provided in the filing.
- The filing is a routine Regulation FD disclosure with limited substantive news.

## SEC filing metadata
- accession: 0001193125-26-045526
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2026-02-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312526045526/0001193125-26-045526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312526045526/nmra-20260211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-045526
- JSON: https://secwatch.observer/filing/0001193125-26-045526.json
- Plain text: https://secwatch.observer/filing/0001193125-26-045526.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.